MYOS RENS Announces Several Leading Pet Insurance Companies Now Covering Its Canine Nutrition Products

0

The following pet insurers now cover MYOS Canine Muscle Formula: Nationwide Pet Insurance, Pet insurance Trupanion, Take up pet insurance, PetPlan Insurance, Hartville Pet Insurance / Pet Health Care Plan, Prudent pet insurance, and PetPartners pet insurance. Coverage is on a case-by-case basis and each insurance company should be contacted in advance for details.

Veterinary costs represent $ 58.5 billion in expenses, each year, according to the North American Pet Health Insurance Association (NAPHIA), and pet insurers reimburse approximately $ 15.25 billion of these veterinary care costs each year. Many of these insurers also reimburse a large portion of the cost of nutritional supplements when prescribed by a veterinarian..

“I have been using Fortetropin in dogs for almost 5 years. I find it particularly useful in older dogs and dogs with muscle atrophy,” said Leilani Alvarez, DVM, DACVSMR, Director, Integrative and Rehabilitation Medicine, Animal Medical Center, New York, New York State, an expert in veterinary nutraceuticals who is well published in this field. “It is rare to have veterinary supplements backed by prospective clinical studies and Fortetropin, which has been rigorously studied, is a leader in this regard,” she added.

A large number of human and veterinary clinical studies have shown that gains in muscle mass and muscle strength are associated with improved longevity in humans and animals. Additionally, specific veterinary clinical research has also shown that Labrador Retriever dogs with greater muscle mass have improved longevity.

“The decision of many vets to recommend MYOS Canine to their patients is a testament to the effectiveness of our product which is supported by clinical research, “declared Joseph mannello, CEO of MYOS. “There is overwhelming evidence linking muscle health to improved longevity, and we believe MYOS Canine is a great investment in your dog’s muscle health. We will continue to work with veterinarians and pet insurance companies. to provide pet owners with a product proven to improve their dog’s muscle health. “

About Myos Canine Muscle Formula®
Myos Canine Muscle Formula (Ordinary and Veterinary force) is an advanced veterinary health supplement to support muscle health in dogs, comprising Fortetropin® as an active ingredient. Fortetropin is made through a patented process that maintains vital nutrients in fertilized egg yolks to help build more lean muscle and reduce muscle loss. For more information, please visit www.myospet.com.

About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), “The Muscle Company®“, is a Cedar Knolls, New Jerseyadvanced nutrition company that develops and markets products that improve muscle health and performance. MYOS owns Fortetropin®, a product based on fertilized egg yolk produced using an exclusive process to conserve and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass, and reduce muscle wasting. MYOS believes that Fortetropin has the potential to redefine existing standards of physical health and well-being. For more information, please visit www.myosrens.com.

Forward-looking statements
All statements contained in this press release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, those relating to products and customer demand, market acceptance of our products, the ability to create new products through research and development, the positive results of strategic initiatives, the success of our products, including MYOS Canine Muscle Formula®, yellowed®, Doctor Muscle Health Formula®, Qurr® and MYOS Enteral Nutrition Formula, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to seize new partnership opportunities and the success of our existing partnerships, the ability to generate income and cash flow from the sales of our products, the ability to increase our revenues and margins gross beneficiaries, the ability to achieve a sustainable and profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other suppliers and products, the continued listing of our securities in the market Nasdaq stock market, risks in product development, our ability to raise capital to finance continuing operations, the negative impact of the coronavirus on the economy and our business, and other factors discussed from time to time in our filings with the Securities and Exchange Commission. We assume no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made, except as required by law.

Investor Relations:
MYOS RENS technology
Joanne goodford
Telephone: 973-509-0444
E-mail: [email protected]

SOURCE MYOS RENS Technology Inc.

Related links

http://www.myosrens.com


Source link

Leave A Reply

Your email address will not be published.